The Regional University Hospital of Málaga is participating in an innovative study aimed at evaluating an oral treatment for hemophilia A, as part of the international clinical trial VOYAGER2. This centre is one of the two hospitals in Spain selected for this trial, alongside La Paz University Hospital in Madrid.
Details of the VOYAGER2 trial
Hemophilia A is a chronic bleeding disorder caused by a deficiency of clotting factor VIII, which is essential for proper blood coagulation. Those suffering from this condition are at risk of prolonged bleeding or spontaneous hemorrhages, especially in joints and muscles.
Currently, treatment for hemophilia A involves the administration of intravenous infusions that must be repeated several times a week, which represents a burden for both patients and their families.
Innovations in treatment
The VOYAGER2 trial represents the first attempt to replace intravenous administration with an oral treatment. This new approach is based on a monoclonal antibody that mimics the function of factor VIII, facilitating the coagulation process without directly supplying the missing protein.
Francisco López, a hematologist at the Regional Hospital and the principal investigator of the study, has pointed out that this advancement could signify a significant change in the treatment of hemophilia. Such innovation has the potential to greatly improve the quality of life for patients.
Dr. Manuel Isidro Muñoz, head of the Hematology department, added that simplifying treatment could contribute to improved well-being and allow for a more independent life for young people with hemophilia, who have faced a complex treatment regimen since childhood.
Although the trial is in its early stages, it is a crucial step in assessing the safety and effectiveness of this new treatment. If its viability is confirmed, it could transform the way this disease is managed in the near future.
You may also like
